Current opinion on optimal treatment for colorectal cancer

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 597-611

  Price, Timothy J ^a   Segelov, Eva ^b   Burge, Matthew ^c   Haller, Daniel G ^d   Ackland, Stephen P ^e   Tebbutt, Niall C ^f   Karapetis, Christos S ^g   Pavlakis, Nick ^h   Sobrero, Alberto F ⁱ   Cunningham, David ^j   Shapiro, Jeremy D ^k  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^f AUSTIN HEALTH   (Australia)

^g FLINDERS MEDICAL CENTRE   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k MONASH UNIVERSITY   (Australia)

more..

Author keywords

biological; chemotherapy; colorectal cancer; consensus; KRAS; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL PRODUCT; BRIVANIB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; NRAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; REGORAFENIB; ROFECOXIB; TAS 102; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ASTHENIA; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CARDIOTOXICITY; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; GENE; HUMAN; HYPERTENSION; KRAS GENE; MEDICAL DECISION MAKING; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROTEINURIA; QUALITY OF LIFE; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DECISION MAKING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876857968     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.37     Document Type: Review

References (89)

1. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J. Clin. Oncol. 23(36), 9441-9442 (2005).
2. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), 2020-2029 (2007).
3. Yothers GA, Allegra CJ, O'Connell MJ et al. The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3-7 June 2011 (Abstract 3507).
4. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracilbased adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219-3226 (2010).
5. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19), 3109-3116 (2009).
6. Romanus D, Weiser MR, Skibber JM et al. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J. Natl Compr. Canc. Netw. 7(8), 895-904 (2009).
7. André T, Boni C, Mounedji-Boudiaf L et al.; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
8. Yothers G, O'Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol. 29(28), 3768-3774 (2011).
9. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol. 29(11), 1465-1471 (2011).
10. Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-fluorouracil/ folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann. Oncol. 23(5), 1190-1197 (2012).
11. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25(23), 3456-3461 (2007).
12. Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/ leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27(19), 3117-3125 (2009).
13. Allegra CJ, Yothers G, O'Connell MJ et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31(3), 359-364 (2013).
14. de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial. Lancet Oncol. 13(12), 1225-1233 (2012).
15. Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J. Clin. Oncol. 29(1), 1-4 (2011).
16. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8(4), 210-221 (2011).
17. Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307(13), 1383-1393 (2012).
18. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
19. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J. Clin. Oncol. 30(31), 3827-3833 (2012).
20. Rödel C, Liersch T, Becker H et al.; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ ARO/AIO-04 randomised Phase 3 trial. Lancet Oncol. 13(7), 679-687 (2012).
21. Gérard JP, Azria D, Gourgou-Bourgade S et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. 30(36), 4558-4565 (2012).
22. Chen CF, Huang MY, Huang CJ et al. A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. Int. J. Colorectal Dis. 27(6), 727-736 (2012).
23. Midgley RS, McConkey CC, Johnstone EC et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol. 28(30), 4575-4580 (2010).
24. Lundberg GD. Aspirin helps prevent recurring colorectal adenomas -folic acid does not. Medscape J. Med. 10(3), 69 (2008).
25. Ali R, Toh HC, Chia WK; ASCOLT Trial Investigators. The utility of aspirin in Dukes C and high risk Dukes B colorectal cancer -the ASCOLT study: study protocol for a randomized controlled trial. Trials 12, 261 (2011).
26. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367(17), 1596-1606 (2012).
27. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012).
28. Nordlinger B, Sorbye H, Glimelius B et al.; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617), 1007-1016 (2008).
29. Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann. Surg. Oncol. 16(9), 2385-2390 (2009).
30. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg. 240(4), 644-657; discussion 657 (2004).
31. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
32. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1), 38-50 (2007).
33. Seymour MT, Maughan TS, Ledermann JA et al.; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582), 143-152 (2007).
34. Colucci G, Gebbia V, Paoletti G et al.; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23(22), 4866-4875 (2005).
35. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum -applying current evidence to clinical practice. Cancer Treat. Rev. 38(5), 397-406 (2012).
36. Falcone A, Ricci S, Brunetti I et al.; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 25(13), 1670-1676 (2007).
37. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluoro-uracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer 94(6), 798-805 (2006).
38. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008).
39. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
40. Giantonio BJ, Catalano PJ, Meropol NJ et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
41. Puthillath A, Patel A, Fakih MG. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Onco. Targets. Ther. 2, 1-15 (2009).
42. Clarke SJ, Karapetis CS, Gibbs P et al. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit. Rev. Oncol. Hematol. 85(2), 121-135 (2013).
43. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311-2319 (2008).
44. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
45. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
46. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
47. Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010).
48. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
49. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30(29), 3570-3577 (2012).
50. Guerrero S, Casanova I, Farré L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon mutation or proto-oncogene overexpression. Cancer Res. 60(23), 6750-6756 (2000).
51. Peeters M. KRAS mutations in colorectal trials using panitumumab. Ann. Oncol. (2011).
52. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 12(6), 594-603 (2011).
53. Maughan TS, Adams RA, Smith CG et al.; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet 377(9783), 2103-2114 (2011).
54. Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011).
55. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDICVII study. J. Clin. Oncol. 30(15), 1755-1762 (2012).
56. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
57. Seymour MT, Brown SR, Richman S et al. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J. Clin. Oncol. 29, Abstract 3523 (2011).
58. Adams RA, Meade AM, Madi A et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br. J. Cancer 100(2), 251-258 (2009).
59. Grothey A, Lenz HJ, Cats A et al. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J. Clin. Oncol. 30(15), 1735-1737 (2012).
60. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
61. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
62. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6(8), 465-477 (2009).
63. Lise M, Da Pian PP, Nitti D, Pilati PL. Colorectal metastases to the liver: present results and future strategies. J. Surg. Oncol. Suppl. 2, 69-73 (1991).
64. Bismuth H, Adam R, Navarro F, Castaing D, Engerran L, Abascal A. Re-resection for colorectal liver metastasis. Surg. Oncol. Clin. N. Am. 5(2), 353-364 (1996).
65. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8(4), 347-353 (2001).
66. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16(8), 1311-1319 (2005).
67. Leichman L. The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer. Surg. Oncol. Clin. N. Am. 16(3), 537-56, viii (2007).
68. Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist 17(2), 201-211 (2012).
69. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26(33), 5326-5334 (2008).
70. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 16(2), 125-131 (2010).
71. Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48(10), 1466-1475 (2012).
72. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised Phase trial. Lancet Oncol. 11(1), 38-47 (2010).
73. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135-142 (2007).
74. Ducreux M, Malka D, Mendiboure J et al.; Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, Phase 3 trial. Lancet Oncol. 12(11), 1032-1044 (2011).
75. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J. Clin. Oncol. 28(19), 3191-3198 (2010).
76. Price TJ, Zannino D, Wilson K et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann. Oncol. 23(6), 1531-1536 (2012).
77. Price TJ, Townsend AR, Beeke C et al. 'Watchful waiting' for metastatic colorectal cancer, antediluvian or an option to be considered again? Asia. Pac. J. Clin. Oncol. 8(1), 10-13 (2012).
78. Doroshow JH, Synold TW, Gandara D et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. 30(4 Suppl. 15), 14-19 (2003).
79. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park, N.Y.) 19(8), 1057-1063; discussion 1063 (2005).
80. Ong SY, Clarke SJ, Bishop J, Dodds HM, Rivory LP. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer. Drugs 12(7), 619-625 (2001).
81. Townsend AR, Bishnoi S, Broadbridge V et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am. J. Clin. Oncol. 36(1), 49-52 (2013).
82. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer -a GERCOR study. J. Clin. Oncol. 24(3), 394-400 (2006).
83. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J. Clin. Oncol. 27(34), 5727-5733 (2009).
84. Labianca R, Sobrero A, Isa L et al.; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann. Oncol. 22(5), 1236-1242 (2011).
85. Neo EL, Beeke C, Price T et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J. Surg. 81(5), 352-357 (2011).
86. Bennouna J, Sastre J, Arnold D et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 14(1), 29-37 (2013).
87. Grothey A, Sobrero AF, Siena S et al. Results of a Phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. Presented at: 2012 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 19-21 January 2012 (Abstract LBA385).
88. Yoshino T, Mizunuma N, Yamazaki K et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a doubleblind, randomised, placebo-controlled Phase 2 trial. Lancet Oncol. 13(10), 993-1001 (2012).
89. Siu LL, Shapiro JD, Jonker DsJ et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J. Clin. Oncol. 30(Suppl. 4), Abstract 386 (2012).